Andrew I Minchinton

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. pmc Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin
    Jennifer H E Baker
    Integrative Oncology Radiation Biology Unit, BC Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS ONE 8:e76832. 2013
  2. ncbi request reprint Drug penetration in solid tumours
    Andrew I Minchinton
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada
    Nat Rev Cancer 6:583-92. 2006
  3. ncbi request reprint Exploring vascular dysfunction caused by tirapazamine
    Lynsey A Huxham
    Department of Medical Biophysics, British Columbia Cancer Research Centre, 675 West 10th Ave, Vancouver, British Columbia, Canada V5Z 1L3
    Microvasc Res 75:247-55. 2008
  4. doi request reprint Targeting quiescent tumor cells via oxygen and IGF-I supplementation
    Alastair H Kyle
    BC Cancer Research Centre, Department of Integrative Oncology, Vancouver, British Columbia, Canada
    Cancer Res 72:801-9. 2012
  5. doi request reprint Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging
    Lauren J Bains
    Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada
    Int J Radiat Oncol Biol Phys 74:957-65. 2009
  6. ncbi request reprint Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts
    Lynsey A Huxham
    Medical Biophysics Department, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Radiother Oncol 78:138-45. 2006
  7. doi request reprint Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin
    Jennifer H E Baker
    Medical Biophysics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:7260-71. 2008
  8. pmc The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
    Wieslawa H Dragowska
    Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada
    BMC Cancer 11:420. 2011
  9. ncbi request reprint Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin
    Wieslawa H Dragowska
    Department of Advanced Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC, Canada, V5Z 1L3
    Breast Cancer Res Treat 106:319-31. 2007
  10. doi request reprint Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 7:59-70. 2008

Collaborators

Detail Information

Publications27

  1. pmc Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin
    Jennifer H E Baker
    Integrative Oncology Radiation Biology Unit, BC Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS ONE 8:e76832. 2013
    ..This strategy illustrates a novel use of hypoxia-activated cytotoxic prodrugs as vascular targeting agents, and also represents a novel mechanism for targeting tumour vessels. ..
  2. ncbi request reprint Drug penetration in solid tumours
    Andrew I Minchinton
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada
    Nat Rev Cancer 6:583-92. 2006
    ....
  3. ncbi request reprint Exploring vascular dysfunction caused by tirapazamine
    Lynsey A Huxham
    Department of Medical Biophysics, British Columbia Cancer Research Centre, 675 West 10th Ave, Vancouver, British Columbia, Canada V5Z 1L3
    Microvasc Res 75:247-55. 2008
    ..In support of this hypothesis preliminary experiments showed NOS inhibition with L-NNA (N-omega-nitro-L-arginine) increases tumor necrosis, 1 day after administration, in our HCT-116 tumor model...
  4. doi request reprint Targeting quiescent tumor cells via oxygen and IGF-I supplementation
    Alastair H Kyle
    BC Cancer Research Centre, Department of Integrative Oncology, Vancouver, British Columbia, Canada
    Cancer Res 72:801-9. 2012
    ..Thus, our findings pointed to IGF-I receptor stimulation as a rational strategy to successfully increase tumor responsiveness to cytotoxic chemotherapy...
  5. doi request reprint Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging
    Lauren J Bains
    Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada
    Int J Radiat Oncol Biol Phys 74:957-65. 2009
    ..To determine whether vascular-targeting effects can be detected in vivo using magnetic resonance imaging (MRI)...
  6. ncbi request reprint Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts
    Lynsey A Huxham
    Medical Biophysics Department, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Radiother Oncol 78:138-45. 2006
    ..To investigate this apparent paradox we examined the microregional effects of tirapazamine in vivo by mapping drug effects with respect to the position of blood vessels in tumour cryosections...
  7. doi request reprint Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin
    Jennifer H E Baker
    Medical Biophysics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:7260-71. 2008
    ..To examine the antitumor effects of Irinophore C, a nanopharmaceutical formulation of irinotecan, on the tissue morphology and function of tumor vasculature in HT-29 human colorectal tumors...
  8. pmc The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
    Wieslawa H Dragowska
    Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada
    BMC Cancer 11:420. 2011
    ..Here, we assessed feasibility of combining the EGFR inhibitor gefitinib and the mTOR inhibitor everolimus (RAD001) for treating HER2 overexpressing breast cancers with different sensitivity to TZ...
  9. ncbi request reprint Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin
    Wieslawa H Dragowska
    Department of Advanced Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC, Canada, V5Z 1L3
    Breast Cancer Res Treat 106:319-31. 2007
    ..Chou and Talalay analysis of the data suggested that combination of gefitinib and rapamycin was synergistic (CI < 1) at a number of selected drug ratios and over a broad range of effective doses...
  10. doi request reprint Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 7:59-70. 2008
    ..The therapeutic effects of a selected ILK inhibitor (QLT0267) should be determined in the clinic in cancers that exhibit dysregulated ILK, such as PTEN-null glioblastomas...
  11. ncbi request reprint Microregional effects of gemcitabine in HCT-116 xenografts
    Lynsey A Huxham
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Cancer Res 64:6537-41. 2004
    ..We show a differential effect on cell proliferation in relation to vasculature and conclude that cells distal to blood vessels are less affected by gemcitabine probably because of limited penetration...
  12. doi request reprint Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts
    Jennifer H E Baker
    Medical Biophysics Department, British Columbia Cancer Research Center, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:2171-9. 2008
    ..We assessed and mapped the distribution of systemically given, unlabeled trastuzumab at micrometer resolution in tumor xenografts using immunohistochemistry...
  13. doi request reprint Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium
    Clement Mugabe
    University of British Columbia, Vancouver, BC V6T 1Z3, Canada
    Biomaterials 33:692-703. 2012
    ....
  14. ncbi request reprint Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors
    Alastair H Kyle
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Clin Cancer Res 13:2804-10. 2007
    ..Taxanes represent a class of drugs that are currently undergoing a new round of development, but with little known of their ability to penetrate and distribute relative to blood vessels within solid tumors...
  15. ncbi request reprint Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism
    Alexandre Patenaude
    Authors Affiliations Genome Sciences Centre Integrative Oncology Program Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer Res 74:2402-11. 2014
    ..This study uncovers a novel mechanism of nitric oxide production in endothelial cells in tumors, with implications for understanding the peculiar character of tumor blood vessels...
  16. ncbi request reprint Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assay
    Jennifer H E Baker
    Department of Medical Biophysics, British Columbia Cancer Research Centre, 675 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 1L3
    Microvasc Res 71:69-75. 2006
    ....
  17. doi request reprint In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer
    Clement Mugabe
    Faculty of Pharmaceutical Sciences, Departments of Urologic Sciences and Pathology and Laboratory Medicine and Chemistry, Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 17:2788-98. 2011
    ..The present work describes the development and in vitro and in vivo evaluation of a mucoadhesive nanoparticulate docetaxel (DTX) formulation for intravesical bladder cancer therapy...
  18. ncbi request reprint Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture
    Alastair H Kyle
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Cancer Res 64:6304-9. 2004
    ..This model could be applied as a simple anticancer drug development screen to discover drugs that exhibit desirable penetration properties...
  19. ncbi request reprint HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization
    Wieslawa H Dragowska
    Department of Advanced Therapeutics, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Mol Cancer Res 2:606-19. 2004
    ..These results suggest that HER-2/neu overexpression may be linked with overall increased tumor viability and a significant increase in the population of viable hypoxic cells, which is not due to differences in tumor vascularization...
  20. doi request reprint A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation
    Victor W Ho
    The Terry Fox Laboratory, BC Cancer Research Centre, BC Cancer Agency, Department of Pediatrics, Division of Gastroenterology, BC Children s Hospital and University of British Columbia, Vancouver, British Columbia, Canada
    Cancer Res 71:4484-93. 2011
    ..Taken together, our findings offer a compelling preclinical illustration of the ability of a low CHO diet in not only restricting weight gain but also cancer development and progression...
  21. pmc Opposing roles for CD34 in B16 melanoma tumor growth alter early stage vasculature and late stage immune cell infiltration
    Steven Maltby
    The Biomedical Research Centre, University of British Columbia, Vancouver, Canada
    PLoS ONE 6:e18160. 2011
    ..In aggregate, our analysis reveals a novel role for CD34 in both early and late tumor growth and provides novel insights into the role of the tumor microenvironment in tumor progression...
  22. ncbi request reprint Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent
    Alastair H Kyle
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, British Columbia, V5Z 1L3 Canada
    Cancer Res 63:5707-11. 2003
    ..The area under the curve for a 100 mg/kg BrdUrd dose in mice was found to be approximately 30 micro M x h...
  23. ncbi request reprint SHIP represses the generation of alternatively activated macrophages
    Michael J Rauh
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
    Immunity 23:361-74. 2005
    ..Our results suggest that SHIP functions in vivo to repress M2 skewing and that macrophage polarization can occur during differentiation in response to TGFbeta if progenitors have elevated PIP3...
  24. ncbi request reprint The impact of complement activation on tumor oxygenation during photodynamic therapy
    Ivana Cecic
    British Columbia Cancer Agency, Vancouver, BC, Canada
    Photochem Photobiol 83:1049-55. 2007
    ..This study indicates that complement activation in PDT-treated tumors that varies with different photosensitizers is an important determinant of tumor oxygen limitation effects directly associated with photodynamic action...
  25. doi request reprint Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition
    Christopher Daly
    Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA
    Cancer Res 73:108-18. 2013
    ..Thus, blockade of Ang2 might enhance the clinical benefits currently provided by anti-VEGF agents. ...
  26. pmc Vascularization predicts overall survival and risk of transformation in follicular lymphoma
    Pedro Farinha
    Pathology, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, Canada
    Haematologica 95:2157-60. 2010
    ..05, P=0.001 and P=0.01, respectively) and IPI and TVD(90) predicted risk of transformation (P=0.008 and P=0.08, respectively). Increased angiogenesis is an independent marker of inferior survival and may promote transformation...
  27. ncbi request reprint Carbogen breathing after irradiation enhances the effectiveness of tirapazamine in SiHa tumors but not SCCVII tumors in mice
    Andrew I Minchinton
    Medical Biophysics Department, British Columbia Cancer Research Centre, 601 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
    Radiat Res 158:94-100. 2002
    ..These findings suggest that the effectiveness of tirapazamine and other hypoxic cytotoxins may be dependent on tumor type...